BackgroundThe COVID-19 pandemic, driven by the SARS-CoV-2 virus, has posed significant global health challenges, exacerbated by the emergence of the highly mutable Omicron variant. This study explores the potential of bispecific antibodies (bsAbs) in neutralizing this variant more effectively compared to traditional monoclonal antibodies (mAbs) and their combinations.Materials and methodsA comprehensive approach was utilized involving a fully human antibody phage-display library, Omni-Mab, to identify and enrich phage clones specific to SARS-CoV-2.
Recombinant spike receptor-binding domain (RBD) proteins from the Omicron variant and other strains served as antigens during the biopanning process to ensure a broad screening. Post-enrichment, the binding affinity of the antibodies to the spike proteins of various strains was rigorously evaluated.
Antibodies demonstrating strong binding efficacy were strategically combined and engineered into bsAbs.
Frontiers in Immunology published a clinical update in Infectious Disease on 17 Jun 2026.
The item focuses on Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants.
Review the original article for the full source wording and details.